{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:52:50Z","timestamp":1783529570444,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Ministry of Health, Labour and Welfare of Japan","award":["23FC1048"],"award-info":[{"award-number":["23FC1048"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Machine learning (ML) is a valuable tool in healthcare, enabling the prediction of disease progression through data-driven regression and nonlinear modeling. Unlike traditional statistical methods, ML can identify complex interactions among explanatory variables. Autosomal dominant polycystic kidney disease (ADPKD) is a common cause of chronic kidney disease (CKD), often progressing to end-stage renal failure. Accurately predicting CKD progression in ADPKD patients is essential for personalized treatment strategies. This study analyzed data from 2,737 patients with ADPKD enrolled in the Japanese Nationwide Cohort. Using this dataset, we developed ML models to predict CKD stages. Feature importance analysis was performed to identify key predictive variables. Three ML models\u2014random forest, support vector machine, and na\u00efve Bayes\u2014were evaluated for their predictive accuracy. Random forest exhibited the highest predictive accuracy among the models tested. Feature importance analysis identified estimated glomerular filtration rate (eGFR), serum creatinine, CKD heat map, urinary protein, and total kidney volume as the most significant predictors of CKD stage. As a nonlinear model, random forest effectively captured complex interactions between variables, outperforming the linear support vector machine. The na\u00efve Bayes model, despite assuming independence among variables, surpassed the linear model, indicating limited interdependence among some predictors. ML, particularly random forest, provides a robust approach for predicting CKD stages in patients with ADPKD by accounting for nonlinear variable relationships. These findings emphasize ML\u2019s potential in personalized CKD management and highlight the need for individualized treatment approaches.<\/jats:p>","DOI":"10.1038\/s41598-026-39885-7","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T13:47:21Z","timestamp":1770990441000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Machine learning for predicting CKD stages in patients with autosomal dominant polycystic kidney disease: a nationwide cohort study in Japan"],"prefix":"10.1038","volume":"16","author":[{"given":"Yosuke","family":"Shimada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saori","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Hoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiju","family":"Hiromura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Isaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Muto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"39885_CR1","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1001\/jama.2017.18391","volume":"319","author":"AL Beam","year":"2018","unstructured":"Beam, A. L. & Kohane, I. S. Big data and machine learning in health care. JAMA 319, 1317 (2018).","journal-title":"JAMA"},{"key":"39885_CR2","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/nmeth.4642","volume":"15","author":"D Bzdok","year":"2018","unstructured":"Bzdok, D., Altman, N. & Krzywinski, M. Statistics versus machine learning. Nat. Methods 15, 233\u2013234 (2018).","journal-title":"Nat. Methods"},{"key":"39885_CR3","doi-asserted-by":"crossref","unstructured":"Rajula, H. S. R., Verlato, G., Manchia, M., Antonucci, N. & Fanos, V. Comparison of conventional statistical methods with machine learning in medicine: diagnosis, drug development, and treatment. Med. (Mex.) 56, 455 (2020).","DOI":"10.3390\/medicina56090455"},{"key":"39885_CR4","doi-asserted-by":"crossref","unstructured":"Bzdok, D. October. Classical statistics and statistical learning in imaging neuroscience. Front. Neurosci. ;11, 7856 (2017).","DOI":"10.3389\/fnins.2017.00543"},{"key":"39885_CR5","doi-asserted-by":"crossref","unstructured":"Ushio, Y. et al. Machine learning for morbid glomerular hypertrophy. Sci. Rep. 12, 2563 (2022).","DOI":"10.1038\/s41598-022-23882-7"},{"key":"39885_CR6","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.kint.2016.09.035","volume":"91","author":"A Fabris","year":"2017","unstructured":"Fabris, A. et al. Proteomic-based research strategy identified laminin subunit alpha 2 as a potential urinary-specific biomarker for the medullary sponge kidney disease. Kidney Int. 91, 459\u2013468 (2017).","journal-title":"Kidney Int."},{"key":"39885_CR7","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s12072-021-10176-9","volume":"15","author":"H Kataoka","year":"2021","unstructured":"Kataoka, H. et al. Predicting liver cyst severity by mutations in patients with autosomal-dominant polycystic kidney disease. Hepatol. Int. 15, 791\u2013803 (2021).","journal-title":"Hepatol. Int."},{"key":"39885_CR8","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s10157-012-0741-0","volume":"17","author":"T Mochizuki","year":"2012","unstructured":"Mochizuki, T., Tsuchiya, K. & Nitta, K. Autosomal dominant polycystic kidney disease: recent advances in pathogenesis and potential therapies. Clin. Exp. Nephrol. 17, 317\u2013326 (2012).","journal-title":"Clin. Exp. Nephrol."},{"key":"39885_CR9","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1007\/s10157-021-02097-6","volume":"25","author":"S Nishio","year":"2021","unstructured":"Nishio, S. et al. A digest from evidence-based clinical practice guideline for polycystic kidney disease 2020. Clin. Exp. Nephrol. 25, 1292\u20131302 (2021).","journal-title":"Clin. Exp. Nephrol."},{"key":"39885_CR10","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1056\/NEJMcp0804458","volume":"359","author":"JJ Grantham","year":"2008","unstructured":"Grantham, J. J. Autosomal dominant polycystic kidney disease. N. Engl. J. Med. 359, 1477\u20131485 (2008).","journal-title":"N. Engl. J. Med."},{"key":"39885_CR11","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1126\/science.272.5266.1339","volume":"272","author":"T Mochizuki","year":"1996","unstructured":"Mochizuki, T. et al. PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein. Science 272, 1339\u20131342 (1996).","journal-title":"Science"},{"key":"39885_CR12","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3390\/jcm9010146","volume":"9","author":"H Kataoka","year":"2020","unstructured":"Kataoka, H. et al. Prediction of renal prognosis in patients with autosomal dominant polycystic kidney disease using PKD1\/PKD2 mutations. J. Clin. Med. 9, 146 (2020).","journal-title":"J. Clin. Med."},{"key":"39885_CR13","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.ekir.2021.12.012","volume":"7","author":"H Kataoka","year":"2022","unstructured":"Kataoka, H. et al. Germline mutations for kidney volume in ADPKD. Kidney Int. Rep. 7, 537\u2013546 (2022).","journal-title":"Kidney Int. Rep."},{"key":"39885_CR14","doi-asserted-by":"publisher","first-page":"520","DOI":"10.2215\/CJN.0000000640","volume":"20","author":"KL Nowak","year":"2025","unstructured":"Nowak, K. L. et al. Overweight Status, Obesity, and progression to ESKD in patients with autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. Nephrol. 20, 520\u2013528 (2025).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"39885_CR15","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S0168-8510(02)00199-9","volume":"64","author":"H Nakatani","year":"2003","unstructured":"Nakatani, H. & Kondo, T. Characteristics of a medical care program for specific diseases in Japan in an era of changing cost-sharing. Health Policy 64, 377\u2013389 (2003).","journal-title":"Health Policy"},{"key":"39885_CR16","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s10157-023-02372-8","volume":"27","author":"H Kataoka","year":"2023","unstructured":"Kataoka, H. et al. Public support for patients with intractable diseases in japan: impact on clinical indicators from nationwide registries in patients with autosomal dominant polycystic kidney disease. Clin. Exp. Nephrol. 27, 809\u2013818 (2023).","journal-title":"Clin. Exp. Nephrol."},{"key":"39885_CR17","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1681\/ASN.2015010016","volume":"27","author":"E Cornec-Le Gall","year":"2016","unstructured":"Cornec-Le Gall, E. et al. The PROPKD score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 27, 942\u2013951 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"39885_CR18","doi-asserted-by":"publisher","first-page":"5133","DOI":"10.3390\/jcm12155133","volume":"12","author":"A Caroli","year":"2023","unstructured":"Caroli, A. & Kline, T. L. Abdominal imaging in ADPKD: beyond total kidney volume. J. Clin. Med. 12, 5133 (2023).","journal-title":"J. Clin. Med."},{"key":"39885_CR19","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.zemedi.2023.08.001","volume":"34","author":"A Raj","year":"2024","unstructured":"Raj, A., Tollens, F., Caroli, A., N\u00f6renberg, D. & Z\u00f6llner, F. G. Automated prognosis of renal function decline in ADPKD patients using deep learning. Zeitschrift f\u00fcr Medizinische Physik 34, 330\u2013342 (2024).","journal-title":"Zeitschrift f\u00fcr Medizinische Physik"},{"key":"39885_CR20","doi-asserted-by":"crossref","unstructured":"Kanatani, Y. et al. National registry of designated intractable diseases in japan: present status and future prospects. Neurol. Med. Chir. 57, 1\u20137 (2017).","DOI":"10.2176\/nmc.st.2016-0135"},{"key":"39885_CR21","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2020.11.003","volume":"99","author":"AK Cheung","year":"2021","unstructured":"Cheung, A. K. et al. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 99, S1\u2013S87 (2021).","journal-title":"Kidney Int."},{"key":"39885_CR22","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"PE Stevens","year":"2024","unstructured":"Stevens, P. E. et al. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int.  105, S117\u2013S314 (2024).","journal-title":"Kidney Int."},{"key":"39885_CR23","doi-asserted-by":"crossref","unstructured":"Kent, D. M., Steyerberg, E. & van Klaveren, D. Personalized evidence based medicine: predictive approaches to heterogeneous treatment effects. BMJ 2018, k4245 (2018).","DOI":"10.1136\/bmj.k4245"},{"key":"39885_CR24","doi-asserted-by":"crossref","unstructured":"Sacrist\u00e1n, J. A. Patient-centered medicine and patient-oriented research: improving health outcomes for individual patients. BMC Med. Inf. Decis. Making 13, 523 (2013).","DOI":"10.1186\/1472-6947-13-6"},{"key":"39885_CR25","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1056\/NEJMp1200070","volume":"366","author":"CL Bardes","year":"2012","unstructured":"Bardes, C. L. Defining patient-centered medicine. N. Engl. J. Med. 366, 782\u2013783 (2012).","journal-title":"N. Engl. J. Med."},{"key":"39885_CR26","unstructured":"Akhondzadeh, S. & Avicenna. E. Personalized medicine: a tailor made medicine. J. Med. Biotechnol. 2014, 191 (2014)."},{"key":"39885_CR27","doi-asserted-by":"crossref","unstructured":"Kravitz, R., Duan, N. & Braslow, J. Evidence\u2010based medicine, heterogeneity of treatment effects, and the trouble with averages. Milbank Q. 82, 661\u2013687 (2004).","DOI":"10.1111\/j.0887-378X.2004.00327.x"},{"key":"39885_CR28","doi-asserted-by":"crossref","unstructured":"Sacrist\u00e1n, J. A. Exploratory trials, confirmatory observations: a new reasoning model in the era of patient-centered medicine. BMC Med. Res. Methodol. 11, 2563 (2011).","DOI":"10.1186\/1471-2288-11-57"},{"key":"39885_CR29","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/cts.12884","volume":"14","author":"KB Johnson","year":"2020","unstructured":"Johnson, K. B. et al. Precision medicine, AI, and the future of personalized health care. Clin. Transl. Sci. 14, 86\u201393 (2020).","journal-title":"Clin. Transl. Sci."},{"key":"39885_CR30","doi-asserted-by":"crossref","unstructured":"Fr\u00f6hlich, H. et al. August. From hype to reality: data science enabling personalized medicine. BMC Med. ;16, 2563 (2018).","DOI":"10.1186\/s12916-018-1122-7"},{"key":"39885_CR31","doi-asserted-by":"crossref","unstructured":"van Breda, W., Hoogendoorn, M., Eiben, A. E. & Berking, M. Assessment of temporal predictive models for health care using a formal method. Comput. Biol. Med. 87, 347\u2013357 (2017).","DOI":"10.1016\/j.compbiomed.2017.06.014"},{"key":"39885_CR32","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1016\/j.ekir.2025.03.020","volume":"10","author":"A Sekine","year":"2025","unstructured":"Sekine, A. et al. Kidney function trajectories with Tolvaptan in ADPKD patients with CKD-G5. Kidney Int. Rep. 10, 1864\u20131873 (2025).","journal-title":"Kidney Int. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39885-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39885-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39885-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:14:22Z","timestamp":1781633662000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39885-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["39885"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-39885-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"assertion":[{"value":"26 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Hiroshi Kataoka belonged to an endowed department sponsored by Otsuka Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., and JMS Co. Ltd. The remaining authors declare no conflicts of interest relevant to this article.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8771"}}